Legalese Disclosure
Individuals, not legal entities, may save one copy of these presentation slides for personal, non commercial purposes only. No other uses of these materials, in whole or in part, are allowed. This includes, but is not limited to, commercial use, reproduction, retransmission, sharing, editing, or creating of derivative works, without the prior written permission of HFSA. Permission may be requested by contacting education@hfsa.org.
Program Overview
It is likely that every cardiovascular clinician has encountered patients with transthyretin amyloid cardiomyopathy (ATTR-CM); it is also possible that some of these cases went unrecognized, misdiagnosed and either inappropriately treated or undertreated. Until recently, cardiologists and other healthcare professionals who manage patients with heart failure (HF) overlooked possible (ATTR-CM) owing to the need for invasive diagnostic testing and a lack of targeted and approved treatments. Substantial advances in the understanding of ATTR-CM have led to enhanced screening and diagnostic approaches and the first approved targeted treatment along with a healthy pipeline of potential therapies.
In addition, a recently published American College of Cardiology Expert Consensus Decision Pathway, endorsed by the Heart Failure Society of America, now provides practical and timely guidance on the diagnosis and management of cardiac amyloidosis with an emphasis on the pitfalls in diagnosis and the role of multidisciplinary collaboration in optimizing management. Cardiovascular specialists must have knowledge of the signs, symptoms and other factors that increase the risk for ATTR-CM to identify patients with HF for whom ATTR-CM screening is appropriate. They need to be aware of the current approaches and steps involved in ATTR-CM screening and diagnosis, how to differentiate between hereditary and wild-type ATTR, and the implications of the differential diagnosis. Finally, cardiovascular clinicians benefit from a review of treatment that has been approved for ATTR-CM, in addition to agents in late-stage development, which can facilitate improved quality and quantity of life in HF patients with ATTR-CM.
In this program, experts in cardiac amyloidosis will discuss best practices for identifying HF patients for screenign for ATTR-CM, explain screening and diagnostic approaches, and describe current and emerging treatments for ATTR-CM
Target Audience
This educational activity is intended for clinicians treating patients with heart failure.
Educational Objectives
Upon completion of this activity, participants should be able to:
- Identif factors that raise the suspicion for ATTR-CM in patients with heart failure.
- Discuss the screening and diagnostic process for ATTR-CM.
- Assess efficacy, safety, and dosing considerations for available targeted therapy for ATTR-CM.
- Explain the clinical trial data on new and emerging agents under investigation for the management of ATTR-CM.
Agenda
Introduction
MaMaurer, MD (Chair)
Raising Awareness, Screening and Diagnosing ATTR-CM in Patients with Heart Failure
Ahmad Masri, MD, MS
Current and Emerging Therapies for ATTR-CM in Patients with Heart Failure
Matthew Maurer, MD
Case Presentations: Best Practices for Recognizing, Diagnosing and Managing ATTR-CM in Patients with Heart Failure
Presenter: Brett Sperry, MD
Panelists: Ahmad Masri, MD, MS and Matthew Maurer, MD
Question and Answer
Faculty and Disclosures
ChairMatthew Maurer, MD
FacultyAhmad Masri, MD, MS
Brett Sperry, MD
Matthew Maurer
|
Do you have any financial relationships with a JA defined ineligible company or commercial interest related to the content of the activity? YES
|
Company Name
|
Type of Company
|
Relationship
|
Other
|
Has this relationship ended?
|
|
Akcea Therapeutics
|
Pharmaceutical Company/Distributors
|
Advisory Panel
|
|
Ended
|
|
Cytokinetics
|
Pharmaceutical Company/Distributors
|
Advisory Panel
|
|
Current
|
|
Alnylam Pharmaceuticals
|
Pharmaceutical Company/Distributors
|
Advisory Panel
|
|
Current
|
|
Ionis Pharmaceuticals
|
Pharmaceutical Company/Distributors
|
Advisory Panel
|
|
Current
|
|
Intellia Therapeutics
|
Pharmaceutical Company/Distributors
|
Board Member
|
|
Current
|
|
Johnson & Johnson
|
Pharmaceutical Company/Distributors
|
Advisory Panel
|
|
Current
|
|
Pfizer
|
Pharmaceutical Company/Distributors
|
Advisory Panel
|
|
Current
|
|
PurFoods, LLC
|
Medical Foods/Dietary Supplements Grower/Distributor/Manufacturer/Seller
|
Research Support
|
|
Ended
|
|
Janssen
|
Pharmaceutical Company/Distributors
|
Advisory Panel
|
|
Ended
|
|
Novo Nordisk
|
Pharmaceutical Company/Distributors
|
Advisory Panel
|
|
Current
|
|
Abbott Laboratories
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Current
|
|
AstraZeneca
|
Pharmaceutical Company/Distributors
|
Advisory Panel
|
|
Current
|
|
|
|
|
I have read and considered each item in this form and completed it to the best of my ability. I understand that my presentation will be evaluated by participants for fair balance. AGREE
|
|
|
Ahmad Masri
|
Do you have any financial relationships with a JA defined ineligible company or commercial interest related to the content of the activity? YES
|
Company Name
|
Type of Company
|
Relationship
|
Other
|
Has this relationship ended?
|
|
Pfizer
|
Pharmaceutical Company/Distributors
|
Research Support
|
|
Current
|
|
Ionis Pharmaceuticals
|
Pharmaceutical Company/Distributors
|
Research Support
|
|
Current
|
|
Other Company - Ultromics
|
Bio-Medical Startup
|
Research Support
|
|
Ended
|
|
Other Company - Attralus
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Current
|
|
Bristol-Myers Squibb
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Current
|
|
Cytokinetics
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Current
|
|
Alnylam Pharmaceuticals
|
Pharmaceutical Company/Distributors
|
Other Relationship
|
honoraria
|
Ended
|
|
Tenaya Therapeutics
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Current
|
|
Pfizer
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Current
|
|
Ionis Pharmaceuticals
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Current
|
|
Eidos Therapeutics
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Current
|
|
Other Company - Haya
|
Pharmaceutical Company/Distributors
|
Advisory Panel
|
|
Current
|
|
Other Company - BioMarin
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Current
|
|
Lexicon Pharmaceuticals
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Current
|
|
Intellia Therapeutics
|
Pharmaceutical Company/Distributors
|
Consultant
|
|
Current
|
|
|
I have read and considered each item in this form and completed it to the best of my ability. I understand that my presentation will be evaluated by participants for fair balance. AGREE
|
|
|
Bretty Sperry
|
Do you have any financial relationships with a JA defined ineligible company or commercial interest related to the content of the activity? YES
|
Company Name
|
Type of Company
|
Relationship
|
Other
|
Has this relationship ended?
|
|
Pfizer
|
Pharmaceutical Company/Distributors
|
Speaker's Bureau
|
|
Current
|
|
Alnylam Pharmaceuticals
|
Pharmaceutical Company/Distributors
|
Advisory Panel
|
|
Current
|
|
Other Company - BridgeBio
|
Pharmaceutical Company/Distributors
|
Advisory Panel
|
|
Current
|
|
|
I have read and considered each item in this form and completed it to the best of my ability. I understand that my presentation will be evaluated by participants for fair balance. AGREE
|
Accreditation and Credit Designation Statements
Physicians: In support of improving patient care, the Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Heart Failure Society of America designates this live activity for a maximum of
1 AMA PRA Category 1 Credits™. Learners should claim only the credit commensurate with the extent of their participation in the activity.
Nurses: This educational activity is approved for continuing nursing education (CNE) units by the HFSA, an accredited provider of the American Nurses Credentialing Center. This activity is approved for a maximum of 1.0 contact hours. Learners should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacists: The Heart Failure Society of America is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education (CPE). This activity is accredited for 1.0 contact hours of knowledge-based CPE under the ACPE universal activity number JA4008267-0000-21-003-H04-P.
Disclosure StatementIt is the policy of the Heart Failure Society of America (HFSA) to ensure balance, content independent of industry influence, objectivity and scientific rigor in all continuing education (CE) activities, free from the appearance of or actual conflicts of interest (COI).
Educational Grant
Voxmedia and the Heart Failure Society of America (HFSA) gratefully acknowledge the educational grant from AstraZeneca Pharmaceuticals.